Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity

International Journal of Radiation Oncology Biology Physics

Volumn 62, Issue 4, 2005, Pages 981-987

  Allen, Zachariah A ^a   Merrick, Gregory S ^a,b   Butler, Wayne M ^a,b   Wallner, Kent E ^c   Kurko, Brian ^a   Anderson, Richard L ^a   Murray, Brian C ^a   Galbreath, Robert W ^a,b,d  

^a WHEELING HOSPITAL   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Ohio University Eastern   (United States)

Author keywords

Brachytherapy; Prostate; Quality of life; Urinary morbidity

Indexed keywords

DIAPHRAGMS; DOSIMETRY; IMPLANTS (SURGICAL); ONCOLOGY; TUMORS;

BRACHYTHERAPY; INTERNATIONAL PROSTATE SYMPTOM SCORE (IPSS); MORBIDITY; TRANSURETHAL RESECTION OF PROSTATE (TURP);

RADIOTHERAPY;

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CANCER SURGERY; CATHETERIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLOW UP; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SCORING SYSTEM; TRANSURETHRAL RESECTION; URETHRA; URETHRA STRICTURE; URINARY DYSFUNCTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; STATISTICS; URETHRA; URINARY CATHETERIZATION; URINATION DISORDERS;

EID: 21244446127     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.12.068     Document Type: Article

References (30)

1. G.S. Merrick, K.E. Wallner, W.M. Butler Minimizing prostate brachytherapy-related morbidity Urology 62 2003 786 792
2. G.S. Merrick, K.E. Wallner, W.M. Butler Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland J Urol 169 2003 1643 1652
3. G.S. Merrick, W.M. Butler, J.H. Lief Temporal resolution of urinary morbidity following prostate brachytherapy Int J Radiat Oncol Biol Phys 47 2000 121 125
4. A. Hinerman-Mulroy, G.S. Merrick, W.M. Butler Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy Int J Radiat Oncol Biol Phys 59 2004 1367 1382
5. M.D. Terk, R.G. Stock, N.N. Stone Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate J Urol 160 1998 1379 1382
6. D.Y. Gelblum, L. Potters, R. Ashley Urinary morbidity following ultrasound-guided transperineal prostate seed implantation Int J Radiat Oncol Biol Phys 45 1999 56 67
7. S.K. Kang, R.H. Chou, R.K. Dodge Acute urinary toxicity following transperineal prostate brachytherapy using a modified quimby loading approach Int J Radiat Oncol Biol Phys 50 2001 937 945
8. G.S. Merrick, W.M. Butler, K.E. Wallner Dysuria after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 55 2003 979 985
9. J. Crook, A. Toi, M. McLean The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy Brachytherapy 1 2002 131 137
10. G.S. Merrick, W.M. Butler, K.E. Wallner Prophylactic versus therapeutic alpha blockers following permanent prostate brachytherapy Urology 60 2002 650 655
11. J. Desai, R.G. Stock, N.N. Stone Acute urinary morbidity following I-125 interstitial implantation of the prostate gland Radiat Oncol Invest 6 1998 135 141
12. W.R. Lee, R.P. McQuellon, L.D. Case Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer J Urol 162 1999 403 406
13. G.S. Merrick, W.M. Butler, B.G. Tollenaar The dosimetry of prostate brachytherapy-induced urethral strictures Int J Radiat Oncol Biol Phys 52 2002 461 465
14. G.S. Merrick, W.M. Butler, K.E. Wallner Long-term urinary quality of life following permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 56 2003 454 461
15. G.S. Merrick, W.M. Butler, K.E. Wallner Does cigarette smoking influence biochemical outcome following permanent prostate brachytherapy? Int J Radiat Oncol Biol Phys 58 2004 1056 1062
16. J. Crook, M. McLean, C. Catton Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation Int J Radiat Oncol Biol Phys 52 2002 453 460
17. 3 Dosimetric analysis of implant quality Int J Radiat Oncol Biol Phys 46 2000 1199 1204
18. T. Sherenz, K. Wallner, H. Wang Long-term urinary function after transperineal brachytherapy for patients with large prostate glands Int J Radiat Oncol Biol Phys 51 2001 1241 1245
19. G.S. Merrick, W.M. Butler, K.E. Wallner The impact of prostate volume and neoadjuvant androgen deprivation therapy on urinary function following prostate brachytherapy Cancer J 10 2004 181 189
20. K. Wallner, J. Roy, L. Harrison Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy Int J Radiat Oncol Biol Phys 32 1995 465 471
21. N.N. Stone, R.G. Stock Long-term morbidity in patients treated with I-125 prostate brachytherapy followed a minimum of 4 years J Urol 171 Suppl 2004 218 219
22. G.S. Merrick, W.M. Butler, W.H. Farthing The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection J Brachyther Int 14 1998 112 121
23. G.S. Merrick, W.M. Butler Modified uniform seed loading for prostate brachytherapy Rationale, design and evaluation Tech Urol 6 2000 78 84
24. G.S. Merrick, W.M. Butler, A.T. Dorsey Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation Tech Urol 7 2001 233 240
25. R. Nath, L.L. Anderson, G. Luxton Dosimetry of interstitial brachytherapy sources Recommendations from the AAPM Radiation Therapy Committee Task Group no. 43 Med Phys 22 1995 209 234
26. W.M. Butler, G.S. Merrick, A.T. Dorsey Comparison of dose length, area, and volume histograms as qualifiers of urethral dose in prostate brachytherapy Int J Radiat Oncol Biol Phys 48 2000 1575 1582
27. M.J. Barry, W.O. Williford, Y. Chang Benign prostatic hyperplasia specific health status measures in clinical research How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 154 1995 1770 1774
28. K. Wallner, G. Merrick, L. True I-125 versus Pd-103 for low-risk prostate cancer Morbidity outcomes from a prospective randomized multicenter trial Cancer J 8 2002 67 73
29. B.C. Leibovich, M.L. Blute, D.G. Bostwick Proximity of prostate cancer to the urethra Implications for minimally invasive ablative therapies Urology 56 2000 726 729
30. C. Sohayda, P.A. Kupelian, H.S. Levin Extent of extracapsular extension in localized prostate cancer Urology 55 2000 382 386